Patents by Inventor Karen Starko

Karen Starko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
    Patent number: 7364734
    Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: April 29, 2008
    Assignee: Genentech, Inc.
    Inventors: Marvin R. Garovoy, Susan M. Kramer, Russell L. Dedrick, Karen Starko
  • Treatment of LFA-1 Associated Disorders with Increasing Doses of LFA-1 Antagonist
    Publication number: 20080050364
    Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
    Type: Application
    Filed: October 30, 2007
    Publication date: February 28, 2008
    Applicants: Genentech, Inc., Xoma Ltd.
    Inventors: Marvin Garovoy, Susan Kramer, Russell Dedrick, Karen Starko
  • Methods of treating idiopathic pulmonary fibrosis
    Publication number: 20070092488
    Abstract: The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-? to an individual with IPF.
    Type: Application
    Filed: May 14, 2004
    Publication date: April 26, 2007
    Applicant: Intermune Inc.
    Inventors: Robert Strieter, Karen Starko
  • Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
    Publication number: 20050169916
    Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
    Type: Application
    Filed: March 10, 2005
    Publication date: August 4, 2005
    Inventors: Marvin Garovoy, Susan Kramer, Russell Dedrick, Karen Starko
  • Treatment of LFA-1 associated disorders with increasing doses
    Publication number: 20040047859
    Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
    Type: Application
    Filed: September 5, 2003
    Publication date: March 11, 2004
    Applicants: Genentech, Inc., Xoma Ltd.
    Inventors: Marvin R. Garovoy, Susan M. Kramer, Russell L. Dedrick, Karen Starko
  • Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
    Patent number: 6652855
    Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need therof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: November 25, 2003
    Assignees: Genentech, Inc., XOMA Ltd.
    Inventors: Marvin R. Garovoy, Susan M. Kramer, Russell L. Dedrick, Karen Starko